Author | Emily Delzell

Articles

Nearly 90 Percent of PsA Patients Who Use Complementary Medicines Report Benefits

November 11, 2019

Article

ACR Annual Meeting:  More than half of survey psoriatic arthritis patients say they have adopted complementary or alternative medicine strategies and most say they've experienced some benefit, researchers reported November 12 at the annual meeting of the American College of Rheumatology in Atlanta.

EU Consensus Statement on Combined Therapy with Methotrexate

November 11, 2019

Article

ACR Annual Meeting:  Methotrexate should be continued in most patients with active rheumatoid arthritis when biologic or targeted synthetic therapy is initiated, EU researchers reported in a poster presentation on November 12 at the annual meeting of the American College of Rheumatology in Atlanta.

Ustekinumab Linked to Lower Serious Infection Rates in Psoriasis and Psoriatic Arthritis

November 11, 2019

Article

ACR Annual Meeting:  Compared with seven other biologics and a phosphodiesterase-4 inhibitor, the anti-IL-12/23 biologic ustekinumab was associated with a generally lower risk of serious infection requiring hospitalization in psoriasis or psoriatic arthritis patients, researchers reported on November 12 at the American College of Rheumatology annual meeting in Atlanta.

Olokizumab May Offer New Option for RA Patients

November 11, 2019

Article

ACR Annual Meeting:  The anti-IL-6 agent olokizumab was safe and effective when added to methotrexate in patients with rheumatoid arthritis in a phase three randomized controlled trial, researchers reported on November 12 at the American College of Rheumatology annual meeting in Atlanta.

x